Kelsey Goodwin
Stock Analyst at Guggenheim
(0.51)
# 3,910
Out of 4,837 analysts
14
Total ratings
30.77%
Success rate
-15.42%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kelsey Goodwin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| URGN UroGen Pharma | Reiterates: Buy | n/a | $7.54 | - | 2 | Apr 29, 2025 | |
| IPSC Century Therapeutics | Reiterates: Buy | n/a | $0.60 | - | 3 | Mar 28, 2025 | |
| GNLX Genelux | Initiates: Buy | $8 | $2.75 | +190.91% | 1 | Oct 29, 2024 | |
| NUVL Nuvalent | Maintains: Buy | $99 → $105 | $75.96 | +38.23% | 2 | Sep 16, 2024 | |
| MGNX MacroGenics | Downgrades: Neutral | n/a | $1.57 | - | 1 | Jul 31, 2024 | |
| ACLX Arcellx | Maintains: Buy | n/a | $60.54 | - | 3 | Jun 20, 2023 | |
| LEGN Legend Biotech | Initiates: Neutral | n/a | $30.07 | - | 1 | Oct 31, 2022 | |
| IOVA Iovance Biotherapeutics | Initiates: Neutral | n/a | $1.91 | - | 1 | Oct 31, 2022 |
UroGen Pharma
Apr 29, 2025
Reiterates: Buy
Price Target: n/a
Current: $7.54
Upside: -
Century Therapeutics
Mar 28, 2025
Reiterates: Buy
Price Target: n/a
Current: $0.60
Upside: -
Genelux
Oct 29, 2024
Initiates: Buy
Price Target: $8
Current: $2.75
Upside: +190.91%
Nuvalent
Sep 16, 2024
Maintains: Buy
Price Target: $99 → $105
Current: $75.96
Upside: +38.23%
MacroGenics
Jul 31, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.57
Upside: -
Arcellx
Jun 20, 2023
Maintains: Buy
Price Target: n/a
Current: $60.54
Upside: -
Legend Biotech
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $30.07
Upside: -
Iovance Biotherapeutics
Oct 31, 2022
Initiates: Neutral
Price Target: n/a
Current: $1.91
Upside: -